Showing 1,095 results

Filters Content type: News, Editors' picks Topic: Hepatitis C treatment

Direct-acting antiviral medicines interfere with different steps of the hepatitis C lifecycle. A combination of drugs may be co-formulated into a single pill. Modern treatment typically lasts for two or three months, usually does not cause side-effects and cures more than 95% of treated people.

Access to healthcare

Patients Get Extreme to Obtain Hepatitis Drug That's 1% the Cost Outside U.S.

Editor's pick
Bloomberg
2 June 2015
Drug interactions & pharmacokinetics

Almost Three Quarters of HIV/HCV Group May Have DDA-ARV Interactions

Editor's pick
NATAP
2 June 2015
Pharmaceutical industry

Panel: Compulsory licensing could address high-priced medicines in Europe

Editor's pick
Intellectual Property Watch
29 May 2015
Access to healthcare

Consumers Sue Anthem for Denying Coverage for a Hepatitis C Drug

Editor's pick
Wall Street Journal
28 May 2015
Finance & funding

NHS England accused of interference over hepatitis C drug

Editor's pick
Channel 4 News
26 May 2015
Hepatitis C treatment

Hepatitis C treatment for people in prison may be highly cost-effective in England

News
21 May 2015
Hepatitis C treatment

Hepatitis B and C - An Action Plan for Saving Lives in Europe

Editor's pick
European Liver Patients Association
20 May 2015
Hepatitis C treatment

Pricing remains main barrier to HCV eradication

Editor's pick
Digestive Disease Week News
20 May 2015
Pharmaceutical industry

Is Gilead Sciences Its Own Worst Enemy?

Editor's pick
Motley Fool
20 May 2015
Hepatitis C treatment

Statin use associated with lower risk of liver decompensation and death in hepatitis C patients with cirrhosis

News
19 May 2015
Hepatitis C treatment

Investing in hepatitis C drugs could save the economy billions, researchers suggest

Editor's pick
Medical News Today
19 May 2015
Hepatitis C treatment

Civacir immune globulin may help prevent HCV reinfection after liver transplant

News
17 May 2015
New & experimental hepatitis C treatment

Shortening hepatitis C treatment to 6 weeks effective but not perfect for easier-to-treat patients

News
15 May 2015
Hepatitis C treatment

The VA's Hepatitis C Problem

Editor's pick
Newsweek
14 May 2015
Hepatitis C treatment

Sanders Asks VA to Break Patents on Gilead and AbbVie Hep C Drugs

Editor's pick
Wall Street Journal (blog)
13 May 2015
Access to healthcare

WHO moves to improve access to lifesaving medicines for hepatitis C, drug-resistant TB and cancers

Editor's pick
World Health Organization
11 May 2015
Access to healthcare

Gilead: Stop Blocking Access to Hepatitis C Treatment

Editor's pick
Treatment Action Group
5 May 2015
Access to healthcare

Civil Society Groups Tell UNITAID: Support access mechanisms led by civil society, not the pharmaceutical industry

Editor's pick
Hep C Coalition
5 May 2015
Hepatitis C treatment

Egypt opens first factory for locally produced Sovaldi

Editor's pick
News Egypt
5 May 2015
Pharmaceutical industry

Gilead first-quarter profit doubles on strong hepatitis C drug sales

Editor's pick
Reuters
5 May 2015
Hepatitis C treatment

Another study confirms detrimental effects of delaying hepatitis C treatment

News
5 May 2015
New & experimental hepatitis C treatment

When a short course of sofosbuvir/ledipasvir fails, some people can be cured of hepatitis C with a double treatment duration

News
1 May 2015
Hepatitis C treatment

Sofosbuvir-based treatment safe and effective in advanced kidney disease

News
30 April 2015
Hepatitis C treatment

Merck's grazoprevir/elbasvir combo cures 99% of hepatitis C in chronic kidney disease

News
28 April 2015